Ascendis Pharma A/S (ASND): Price and Financial Metrics
ASND Price/Volume Stats
| Current price | $139.92 | 52-week high | $161.00 |
| Prev. close | $140.89 | 52-week low | $66.03 |
| Day low | $137.78 | Volume | 197,847 |
| Day high | $144.41 | Avg. volume | 371,984 |
| 50-day MA | $148.62 | Dividend yield | N/A |
| 200-day MA | $114.55 | Market Cap | 8.15B |
ASND Stock Price Chart Interactive Chart >
Ascendis Pharma A/S (ASND) Company Bio
Ascendis Pharma A/S is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The company was founded in 2006 and is based in Hellerup, Denmark.
Latest ASND News From Around the Web
Below are the latest news stories about ASCENDIS PHARMA A that investors may wish to consider to help them evaluate ASND as an investment opportunity.
Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceCOPENHAGEN, Denmark, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan Mikkelsen, President & Chief Executive Officer, Scott Smith, Executive Vice President & Chief Financial Officer, and Kennett Sprogøe, Ph.D., Executive Vice President, Head of Research & Product Development, will participate in the 42nd Annual J.P. Morgan Healthcare Conference. Details: Event42nd Annual J.P. Morgan Healthcare ConferenceLocationSan Francisco, CADateMonday, January 8, |
Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/weekTransCon CNP is the first investigational product to demonstrate improvements in health-related quality of life and disease impacts in children with achondroplasia COPENHAGEN, Denmark, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new analyses from the blinded and ongoing open-label extension (OLE) portions of ACcomplisH, the Company’s Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon CNP in children ages 2-10 years wit |
TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency– On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and increase in total body lean mass at Week 38 compared to placebo – TransCon hGH was generally safe and well tolerated, similar to daily hGH, with no discontinuations related to study drug – Exploratory post-hoc analysis suggests the same treatment effects on target tissues as daily hGH COPENHAGEN, Denmark, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma |
FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with Hypoparathyroidism– PDUFA goal date is May 14, 2024 COPENHAGEN, Denmark, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company’s resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adult patients with hypoparathyroidism. The agency considered the resubmission a complete, class 2 response and set a Prescription Drug User Fee Act (PDUFA) goal date of May 14 |
Ascendis Pharma Announces Strategic Partnership with Teijin Limited in Japan– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milestones of up to $175 million, transfer pricing, and commercial milestones – Ascendis Pharma is also eligible to receive royalties on net sales in Japan, of up to mid-20’s percent, varying by product COPENHAGEN, Denmark, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasd |
ASND Price Returns
| 1-mo | -2.99% |
| 3-mo | 5.98% |
| 6-mo | 55.47% |
| 1-year | 68.53% |
| 3-year | 11.91% |
| 5-year | 29.86% |
| YTD | 11.09% |
| 2023 | 3.13% |
| 2022 | -9.22% |
| 2021 | -19.34% |
| 2020 | 19.88% |
| 2019 | 122.06% |
Continue Researching ASND
Want to see what other sources are saying about Ascendis Pharma A's financials and stock price? Try the links below:Ascendis Pharma A (ASND) Stock Price | Nasdaq
Ascendis Pharma A (ASND) Stock Quote, History and News - Yahoo Finance
Ascendis Pharma A (ASND) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...